Purple Book reference family · 351(a) biologic
nofetumomab (Verluma)
nofetumomab is an FDA-licensed reference biologic from Boehringer Ingelheim Pharma GmbH & Co. KG.
351(a) biologicBLA 103769 Boehringer Ingelheim Pharma GmbH & Co. KG
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
1998
Reference product
Originator biologic
351(a)BLA 103769
Verluma nofetumomab
Boehringer Ingelheim Pharma GmbH & Co. KG
View full reference-product record- Approved
- Marketing
- Disc
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Protection horizon
Reference approval
Approval date of the reference nofetumomab product.
28 yr 2 mo ago
nofetumomab: frequently asked questions
Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.
Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for nofetumomab.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
